Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence of a new generic formoterol dry powder inhaler vs reference formulations in adult asthma (cumulative dose, four-way crossover)
2005-003826-24Phase 3Completed
- Sponsor
- Andi - Ventis
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of formoterol in asthma (4 arms), sponsored by Andi - Ventis. Primary endpoints: Therapeutic equivalence in bronchodilation (6 µg and 12 µg generic formoterol vs reference formulations) and Safety and tolerability of new generic formoterol dry powder formulations. Started Aug 2005; status: completed.
02
Drugs
formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2005-003826-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003826-24.